文献速递浆细胞疾病造血干细胞移植与细胞治疗

硼替佐米联合来那度胺(VR)巩固治疗不含地塞米松用于移植后多发性骨髓瘤患者:无双膦酸盐情况下的生存与骨结局影响

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
PubMed 文献 · Am J Hematol · 2019-01-10

本研究为开放标签前瞻性研究,评估移植后硼替佐米联合来那度胺(VR)巩固治疗(不含地塞米松和双膦酸盐)的疗效与安全性。59例接受硼替佐米为基础诱导的患者在ASCT后第100天起接受4周期VR巩固。VR后严格完全缓解率从ASCT后的24%升至51%,中位随访62个月无骨骼相关事件,4年和5年OS概率分别为81%和64%。

要点

  • 移植后VR巩固(不含地塞米松和双膦酸盐)可使51%患者达严格完全缓解。
  • VR巩固显著降低sRANKL/OPG比值和硬化蛋白水平,在≥VGPR患者中更明显。
  • 中位随访62个月无骨骼相关事件,中位TTP为37个月,中位OS未达到。

核心结论

  • VR巩固是一种有效、不含地塞米松和双膦酸盐的方案,可提供长OS并改善骨代谢且无骨骼相关事件。

研究设计与样本

  • 开放标签前瞻性研究,纳入59例接受硼替佐米为基础诱导的移植后多发性骨髓瘤患者,ASCT后第100天起接受4周期VR巩固。

主要发现

  • ASCT后58%患者疗效状态改善,VR巩固后39%患者进一步加深缓解。
  • 严格完全缓解率从ASCT后的24%升至VR后的51%。
  • VR巩固显著降低可溶性核因子κB受体活化因子配体/骨保护素比值和硬化蛋白循环水平,在达非常好的部分缓解或更好患者中更明显。
  • 中位随访62个月,无骨骼相关事件发生,尽管未使用双膦酸盐。
  • ASCT后中位TTP为37个月,中位OS未达到;4年和5年OS概率分别为81%和64%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimizing consolidation treatment in transplant-eligible newly diagnosed multiple myeloma patients in order to improve efficacy and bone-related outcomes is intriguing. We conducted an open-label, prospective study evaluating the efficacy and safety of bortezomib and lenalidomide (VR) consolidation after ASCT, in the absence of dexamethasone and bisphosphonates. Fifty-nine patients, who received bortezomib-based induction, were given 4 cycles of VR starting on day 100 post-ASCT. After ASCT, 58% of patients improved their response status, while following VR consolidation 39% further deepened their response; stringent complete response rates increased to 51% after VR from 24% post-ASCT. VR consolidation resulted in a significant reduction of soluble receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio and sclerostin circulating levels, which was more pronounced among patients achieving very good partial response or better. After a median follow-up of 62 months, no skeletal-related events (SREs) were observed, despite the lack of bisphosphonates administration. The median TTP after ASCT was 37 months, while median overall survival (OS) has not been reached yet; the probability of 4- and 5-year OS was 81% and 64%, respectively. In conclusion, VR consolidation is an effective, dexamethasone- and bisphosphonate-free approach, which offers long OS with improvements on bone metabolism and no SREs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Kastritis E, Ntanasis-Stathopoulos I, et al. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. Am J Hematol. 2019. PMID: 30592079. doi:10.1002/ajh.25392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。